keynote-057 cohort b: pembrolizumab for bcg-unresponsive, high-risk nmibc
Published 1 year ago • 118 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
4:05
keynote-057: pembrolizumab monotherapy for high-risk nmibc unresponsive to bcg
-
3:16
keynote-057 update: pembrolizumab for high-risk nmibc patients
-
1:17
keynote-057 cohort c: pembrolizumab with favezelimab or vibostolimab in nmibc
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
5:08
pembrolizumab shows notable anti-tumour activity for patients with high-risk nmibc
-
4:37
keynote-057: outcomes for patients with bcg-unresponsive nmibc who do not respond to pembrolizumab
-
0:57
keynote-676 cohort a: pembrolizumab plus bcg in recurrent hr nmibc
-
10:35
management of bcg unresponsive cystectomy ineligible bladder cancer patients pembrolizumab
-
1:37
dr. balar on next steps of the keynote-057 trial in nmibc
-
3:02
updates from keynote 57: pembrolizumab for patients with bladder cancer
-
9:12
immunotherapy for nmibc: emerging and expanding indications
-
2:08
core1 trial: cg0070 plus pembrolizumab for bcg-unresponsive carcinoma-in-situ bladder cancer
-
1:49
yair lotan, md, shares outcomes of keynote 057 in high-risk non-muscle-invasive bladder cancer
-
1:07
dr. balar discusses keynote-057 study in nmibc
-
0:57
dr. balar on rationale for keynote-057 in nmibc
-
1:33
hot topics in bladder cancer from asco gu 2023
-
1:47
current and upcoming clinical trials in bladder cancer
-
8:08
keynote-029 expansion cohort: pembrolizumab plus ipilimumab ...
-
1:29:54
examining the state of the science on new therapies in bladder cancer